What year will opdivo's patent expire?

When Does Opdivo's Patent Expire?

Opdivo, also known as nivolumab, is a medication developed by Bristol Myers Squibb (BMS) for the treatment of various cancers [1]. The patent for Opdivo has been subject to several extensions and amendments over the years.

Patent Expiration Timeline

As of the latest information available [2], the U.S. Food and Drug Administration (FDA)-approved patent for Opdivo is currently set to expire in 2038.

Impact of Patent Expiration on Market Competition

The expiration of Opdivo's patent will likely lead to increased competition in the market, with generic or biosimilar versions of the medication becoming available [3]. Competitors such as Merck's Keytruda and Roche's Tecentriq may benefit from the patent expiration, potentially leading to market share shifts.

Sources

[1] Bristol Myers Squibb - www.bms.com

[2] DrugPatentWatch.com - www.drugpatentwatch.com

[3] Stat News - www.statnews.com

Sources Cited:

1. www.bms.com
2. www.drugpatentwatch.com
3. www.statnews.com